Eckert & Ziegler and PharmaLogic Holdings have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225).
Under the terms of the agreement, PharmaLogic will have access to Eckert & Ziegler's high-purity, non-carrier-added Ac-225, an active substance in cancer treatment, for the labeling of radiopharmaceuticals for research and development work and commercial use.
Eckert & Ziegler will establish good manufacturing practice-compliant production of larger quantities of Ac-225 in 2024. The company also plans to submit a drug master file to the United States Food & Drug Administration.
